Vir Biotechnology (VIR) Intangibles (2018 - 2026)
Vir Biotechnology (VIR) posted Intangibles of $7.8 million for Q1 2026, down 0.93% sequentially from $7.8 million in Q4 2025, and down 3.65% YoY from $8.1 million in Q1 2025.
Vir Biotechnology (VIR) Intangibles (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Intangibles for 9 years, with the latest figure at $7.8 million in Q1 2026.
- Quarterly Intangibles fell 3.65% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (down 3.65% YoY) and the FY2025 annual result came in at $7.8 million, down 3.33% from the prior year.
- Intangibles slipped to $7.8 million in Q1 2026 per VIR's latest filing, from $7.8 million in the prior quarter.
- Over five years, Intangibles peaked at $33.2 million in Q1 2022 and troughed at $7.8 million in Q1 2026.
- A 5-year average of $20.4 million and a median of $22.5 million in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2022 and 2025: Intangibles retreated 1.58% in 2022, then sank 64.07% in 2025.
- Over 5 years, Intangibles stood at $32.8 million in 2022, then tumbled by 31.11% to $22.6 million in 2023, then sank by 64.02% to $8.1 million in 2024, then dropped by 3.33% to $7.8 million in 2025, then retreated by 0.93% to $7.8 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $7.8 million, $7.8 million, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 7.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.70 Mn |
| Mar 31, 2026 | 7.78 Mn |
| Dec 31, 2025 | 7.85 Mn |
| Sep 30, 2025 | 7.92 Mn |
| Jun 30, 2025 | 8.00 Mn |
| Mar 31, 2025 | 8.07 Mn |
| Dec 31, 2024 | 8.12 Mn |
| Sep 30, 2024 | 19.26 Mn |
| Jun 30, 2024 | 18.90 Mn |
| Mar 31, 2024 | 22.47 Mn |
| Dec 31, 2023 | 22.57 Mn |
| Sep 30, 2023 | 25.46 Mn |
| Jun 30, 2023 | 25.59 Mn |
| Mar 31, 2023 | 32.62 Mn |
| Dec 31, 2022 | 32.76 Mn |
| Sep 30, 2022 | 32.89 Mn |
| Jun 30, 2022 | 33.02 Mn |
| Mar 31, 2022 | 33.15 Mn |
| Dec 31, 2021 | 33.29 Mn |
| Sep 30, 2021 | 33.42 Mn |